Home  »  Environment  »  European Commission Approves Parsabiv™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis

European Commission Approves Parsabiv™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis

Amgen LogoTHOUSAND OAKS, Calif., Nov. 11, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney…

Source: http://www.prnewswire.com/news-releases/european-commission-approves-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adults-on-hemodialysis-300361522.html

About the Author

has written 41528 stories on this site.

«
»
Copyright © 2010 Business and Corporate News.